A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma

NCT04325828 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Salivary Gland Neoplasms

Interventions

DRUG: Apalutamide
DRUG: GnRH Agonist

Sponsor

Janssen Pharmaceutical K.K.